
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
The prevention and treatment of noncommunicable diseases is becoming an increasingly important consideration in global health initiatives.






